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Levels of evidence and 
evidence of levels:
Quo Vadis blood pressure?
COMMENTARY
used only in situations in which there was no scientific data 
available from well controlled trials. The ESH/ESC, British 
Hypertension Society, National Institute of Clinical Excellence 
(NICE) and South African guidelines included more mega-trials 
in their processes.
Evidence suggesting improved compliance with single pill com-
binations has also influenced the drawing up of guidelines.(5) 
The JNC and ISH guidelines currently emphasise the superiority 
of single pill combinations in patients displaying systolic blood 
pressure levels in excess of 20mmHg over threshold values 
and diastolic values in excess of 10mmHg over threshold values. 
The South African guidelines recommend similar management. 
The need for 2 or more agents in stage 2 or 3 hypertension 
cannot be over emphasised.
Clinical guidelines have been determined by data based on 
sustained, elevated blood pressure levels in all studies to date. 
The concept of “variability” has not been a major feature. The 
Anglo-Scandinavian Cardiac Outcomes Trials (ASCOT) results 
has recently reminded us that increased variability, rather than 
mean achieved blood pressure, better predicted stroke and 
coronary heart disease outcomes.(6) This raises the new 
daunting aspect that intermittent hypertension may be more 
deleterious than sustained hypertension over a protracted 
period. If this concept is explored further in future trials it may 
well shape future guidelines.
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Since Lewington published his meta-analysis(1) indicating that 
hypertension is the most important cause of death globally, 
associations have endeavoured to scientifically update guidelines 
regarding thresholds and targets. Healthcare managers and 
clinicians must realise that the condition exacts a similar toll, 
regardless of income status.(2) The European Society of Hyper-
tension (ESH) and the European Society of Cardiology (ESC) 
revised their guidelines following an interval of 6 years. Some 
members of the National Committee (JNC) in the United 
States published their eighth report in 2014. This occurred not 
without controversy as the initial organisers, the National Heart, 
Lung and Blood Institute (NHLBI) which outlined the pro-
cesses, withdrew in June 2013.(3) It opted to partner with 
specific bodies to achieve this aim.(4) Eventually, the remainder 
of the committee pursued their initial goal of addressing 3 
important questions amongst others – thresholds of blood 
pressure to intervene at, targets to achieve and to ascertain if 
there was robust enough evidence to dictate the preferred use 
of a specific agent in a particular clinical situation.
The JNC 8 Committee decided to study only randomised 
controlled trials (RCT) and well conducted meta-analyses 
thereof for their primary recommendations. These recom-
mendations were given an “A” rating. Data with ratings below 
“A” were relegated. Some large scale RCTSs were excluded 
e.g. the ONTARGET study, as the trial did not specify 
hypertension as an admission criterion. Expert opinions were 
There has historically been a series of guidelines for the 
diagnosis and management of elevated blood pressure. 
The recent publication by some members of the Joint 
National Committee (JNC 8), based only on randomised 
controlled trials, has generated much interest in view 
of newer levels for intervention and control. Clinicians 
and policymakers take their cue from these publica-
tions and hence there needs to be critical comment to 
promote rational prescribing. Comorbidities and 
“frailties” must dictate pharmaco-therapeutic choices 
to avoid risk in such patients. Conversely, we must guard 
against physician inertia also if guidelines seem to 
promote “relaxed” targets. This article seeks to cast 




















Curiosities in clinical medicine do occur. After participants in 
the ACCORD(7) trial achieved a lower systolic blood pressure 
in the “intensive “ group, (119mmHg) without any cardiovascular 
benefits, some organisations (notably the American Diabetic 
Association) suggested a return to a target of 140mmHg in such 
patients despite the knowledge that in another trial which 
achieved a similar “intensive” level (ADVANCE)(8) in patients, 
there was a demonstrable mortality benefit of 14%. Many 
doctors were confused for a period of time before guidelines 
were published.
The focus here will be on the JNC 8 recommendations. The 
first recommendation of initiating therapy in the over 60 years 
group at a threshold of 150mmHg systolic blood pressure and 
90mmHg diastolic blood pressure was given an “A” recom-
mendation. The guide is to achieve levels below this, with the 
advice being that if patients achieve levels less than 140mmHg 
(systolic) with no adverse events, then such a patient is to be 
maintained on treatment. The main evidence supporting this 
recommendation comes from the HYVET(9) and Syst-Eur(10) 
studies. Supporting evidence also comes from the JATOS(11) 
and VALISH(12) studies, in which there appeared to be no 
additional benefit of lowering the systolic blood pressure to 
less than 140mmHg in the over 60 years age group .
The panel, as expected, were greatly divided regarding this goal 
blood pressure in the over 60 years age group. The contention 
is that those large meta-analyses and other RCTs with smaller 
numbers, which guided previous recommendations, had not 
been considered. Field experience dictates that in high risk 
groups (Blacks, stroke patients, multiple risk factors) patients 
may be prejudiced if targets such as “less than 150mmHg” are 
recommended. The ESH/ESC and the NICE group recommend 
a level that is different: systolic of 140mmHg or less and diastolic 
of less than 90mmHg in high risk patients.
In the group below 60 years of age, the JNC 8 recommends 
that the threshold for intervention should be 140mmHg and 
90mmHg (systolic and diastolic respectively) and that levels 
should be less than these figures. Here, diastolic blood pressure 
should come to the fore. Trials lending grade A evidence for 
such a recommendation include the ANBP(13) and HDFP(14) 
trials. The hitherto much quoted HOT(15) trial found no favour 
as the trial outcomes did not reach robust statistical significance.
Patients in the younger than 30 years age group are dis-
advantaged in terms of scientific guidelines, as no robust trials 
can guide management. For now most commentators will argue 
that similar recommendations, as in the case of the younger 
than 60 years age group, should apply. Fortunately, all major 
groups (JNC 8, NICE, ESH/ESC) seem to agree in principle that 
if one aims for a diastolic of less than 90mmHg, then the systolic 
blood pressure is bound to be controlled in this group.
The diabetic group of patients, because of high prevalence, was 
of major interest as a subgroup. The JNC 8 recommends that 
intervention should begin at threshold levels of 140mmHg 
systolic blood pressure and 90mmHg diastolic blood pressure, 
and targets are defined as “below 140mmHg” and below 
“90mmHg”. The ACCORD trial group achieved a level of less 
than 140mmHg and both control and intervention groups had 
similar outcomes, apart from stroke reduction. The ADVANCE 
trial groups were not used as evidence as there were no pre-
specified randomised blood pressure thresholds or targets. The 
large UKPDS(16) study did not add value to the JNC 8 paper as 
the study did not pre-specify that the systolic and diastolic 
blood pressure levels were to be critically looked at.
In patients with a reduced glomerular filtration rate of less than 
60ml/min, or albuminuria of 30mg/g of creatinine, the advice is 
to initiate treatment at a threshold level of 140mmHg systolic 
and 90mmHg diastolic blood pressure. Further advice from 
JNC 8 is to “achieve levels of less than 140 and 90mmHg” 
respectively. Surprisingly, there appears to be no “grade A” 
evidence to support a target of less than 130mmHg systolic and 
80mmHg diastolic respectively. Moreover, in the over 70 years 
age group with chronic kidney disease, no evidence exists at all 
for any goal blood pressure. Individualisation of therapy with 
due respect to comorbidities and frailty must guide the deci-
sion making. There is consensus though, in chronic kidney 
disease with proteinuria (>3g/day) and hypertension, to achieve 
a goal of 130/80mmHg. The MDRD study(17) supports this 
conclusion. The KDIGO guidelines do support these targets, 
but the diastolic target is set at a less stringent target of less 
than 90mmHg.
Debates on thresholds and targets are not the only focus of 
interested groups; indeed the selection of specific agents in 
certain clinical situations also remains a focus of interest. Criteria 
for specific agents need to be supported by robust data. In the 
non-black population; placebo comparator trials were not 
included in the JNC 8 analysis. As expected ace inhibitors 
(ACEI) and thiazide diuretics, when used as initial agents, tended 
to have favourable effects on heart failure outcomes. This did 
not preclude a decision to include angiotensin receptor blockers 
(ARB) or calcium channel blockers (CCB) as first line agents. 
The LIFE(18) study however held sway in relegating beta blockers 
from the choice as a first line drug.
It must be stressed that certain groups of anti-hypertensives, 
listed next, are not recommended as first line therapy. These 
include centrally acting drugs, aldosterone antagonists, 
imidazoline receptor antagonists, combined alpha-beta-blockers 
and central sympatholytic agents. There is no robust evidence 
to support their first line usage.
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In Black subjects, the ALLHAT(19) trial, because of pre-speci-
fication of their analysis of subgroups at the outset, provides 
convincing data in this group. Thiazide type diuretics and 
calcium channel blockers are favoured as outcomes appear 
better.(20)
Fortunately all guidelines seem to accept that patients with 
chronic kidney disease, across the spectrum, should have as 
part of their initial therapy a renin angiotensin system blocker 
(ACEI or ARB). In terms of validity of data though, it must be 
stressed that currently the only endpoints showing statistical 
benefit though are renal ones and not cardiovascular. In our 
part of the world, we must specifically address the hypertensive 
Black patient with chronic kidney disease and proteinuria and 
discern whether CCB’s or thiazide diuretics should remain the 
first choice. There are, according to the JNC 8 group, no RCTs 
addressing this point. Expert opinion (level of evidence ranked 
as “E”) favours an ACEI or ARB as the preferred agent to 
preferentially lessen the progression of renal disease. In this 
respect, the superiority of ramipril for renal endpoints in the 
African-American study of Kidney diseases is supportive.(21)
Time frames for achieving the target are just as important as 
knowing the threshold or the target blood pressure. The JNC 8 
guideline suggests a period of 4 weeks. Thereafter, the clini-
cian should have some decision latitude in terms of further 
therapy. Allowance is made for either increasing the dose of 
the initial agent or adding in a second agent. Most national 
guidelines are in accordance with this concept. Expert opinion 
has guided this thinking. Individualisation of therapy and 
enforcement of lifestyle and drug therapy must be continued 
till targets are achieved.
Clinical trials largely exclude patients with comorbidities. In this 
respect, most experts agree that individualisation of therapy 
with senior advice in complex situations is indispensable.
Ambulatory blood pressure monitoring entered clinical prac-
tice about 2 decades ago. This recording must be done on a 
portable machine in the non-dominant arm. The usual duration 
is 24 hours. Intervals favoured are usually 15 minutes (diurnal) 
and 30 minutes (nocturnal), but these may vary from country 
to country. More important is that at least two thirds of all 
recordings must be available for analysis. Average systolic and 
diastolic levels in the time periods are the usual indices which 
guide therapy; most workers use the 10h00 to 20h00 period 
as the waking up or diurnal period and midnight to 06h00 as 
the nocturnal period.(22) In most humans, there is a “dip” or a 
step down of average levels by approximately 10% or more; 
loss of this “nocturnal dip” may be associated with sleep 
apnoea syndrome, chronic kidney disease and dysautonomia as 
common comorbidities. Twenty four hour values have been 
demonstrated to have a stronger relationship to morbidity and 
mortality than office blood pressure measurements.(23,24) This 
is applicable across all ages, both sexes and in treated and 
untreated patients.(25,26) 
Home blood pressure readings also have a common feature in 
general practice. If correctly done on arm devices, it can add 
value as some work has been done to show that the prognostic 
significance may be as good as ABP levels. Generally, devices 
using the brachial artery cuff with 2 readings at different times 
of the day are measured; the initial day’s reading may be 
discarded and an average obtained from a study of the 
remainder of the levels.(27) These may unravel the common 
problem of white coat hypertension (normal home and 
ambulatory readings and higher office readings) as well as 
masked hypertension (normal office readings with high home 
and ambulatory levels). As hypertension is a common disease 
with comorbidities, doctors must seek a higher opinion on 
initiation or change (step up, step down, stoppage) if treatment 
is planned.
Current guidelines may fall short of meeting all the tenets of 
the Institute of Medicine’s (IOM) “Standards of trustworthi-
ness”,(28) but at the least, there has been increased transpar-
ency about conflicts and evidence of quality. We should all 
anticipate updates and revisions, another tenet of the IOM’s 
Standard of trustworthiness. It must be emphasised though 
that most guidelines are reasonably consistent enough with 
respect to definitions, thresholds, targets and choice of first line 
therapy to assist the physician in updated decision making.
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